GeneDx Holdings Corp. (WGS) Stock

GeneDx Holdings Corp. (WGS) is a Healthcare stock trading at $59.08 (as of 2026-07-24), with a market capitalization of $1.75B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

GeneDx Holdings Corp. uses analytics based on artificial intelligence and machine learning to work with clinical and genomic data through its Centrellis health intelligence platform. The company focuses on developing models of human health and related science-driven outputs for disease and wellness, serving healthcare stakeholders and medical needs.

Understand GeneDx Holdings Corp.: how it makes money

GeneDx provides exome and genome genetic testing, and pairs those tests with its Centrellis health intelligence platform that uses AI and machine learning on clinical and genomic data to produce health insights and science-driven solutions.

With an operating margin of -56.2%, the key structural profit challenge is turning exome and genome test revenue into operating profit, rather than being primarily constrained by gross profitability (gross margin is 66.7%).

Revenue by segment (latest quarter)
Exome+Genome$0.1B
Other Panels$0.0B

Business quality (Weak): The latest quarter profile shows strong gross margin but deep operating losses, and the provided revenue breakdown suggests most revenue comes from exome and genome testing versus other panels.

Bull case

  • Integrated testing plus AI-driven health intelligence: GeneDx uses AI and machine learning on multidimensional, longitudinal clinical and genomic data via its Centrellis health intelligence platform.
  • Revenue visibility centered on core testing: Provided segment candidates show Exome and Genome revenue of 0.09B and Other Panels revenue of 0.01B for the latest period.

Bear case

  • Operating losses: Operating margin is -56.2% for the latest period, indicating costs currently exceed operating revenue.
  • Limited diversification beyond exome and genome in the provided breakdown: In the provided segment candidates, Exome and Genome revenue (0.09B) is much larger than Other Panels revenue (0.01B), and several other candidate lines show 0.0B.
Valuation — source: SEC EDGAR (first-party)
Price$59.08
Market Cap$1.75B
Price / Book6.90
Price / Sales3.96
FCF Yield-1.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$427.54M
Net Margin-4.9%
Revenue Growth (YoY)17.4%
EPS Growth (YoY)839.1%
FCF Growth (YoY)-1058.8%
Financial Health — source: SEC EDGAR
Altman Z-Score2.24 (grey)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.2
Industry P/E (Healthcare Services)27.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCorvex Management LP ($207.31M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryHealthcare Services
CEOKatherine A. Stueland
Employees1,000
CountryUS
IPO Date2020-11-04

Related Companies (Business model: Hospital Operator / Acute-Care Provider; 8 closest by market cap; US-domiciled)

  • LifeStance Health Group, Inc. (LFST)
  • Privia Health Group, Inc. (PRVA)
  • InnovAge Holding Corp. (INNV)
  • The Pennant Group, Inc. (PNTG)
  • Omada Health (OMDA)
  • U.S. Physical Therapy, Inc. (USPH)
  • Talkspace, Inc. (TALK)
  • Strata Critical Medical, Inc. (SRTA)
WGS earnings history · WGS institutional & insider holders · WGS KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.